Overview

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

This open-label, multicenter study evaluated the pharmacokinetics, pharmacodynamics and safety of SC administered TCZ in participants with pJIA.

Phase:

Phase 1

Details

Lead Sponsor:

Hoffmann-La Roche